427 related articles for article (PubMed ID: 17727739)
21. Pharmacological outcomes in newly diagnosed epilepsy.
Mohanraj R; Brodie MJ
Epilepsy Behav; 2005 May; 6(3):382-7. PubMed ID: 15820347
[TBL] [Abstract][Full Text] [Related]
22. Lamotrigine-valproic acid combination therapy for medically refractory epilepsy.
Moeller JJ; Rahey SR; Sadler RM
Epilepsia; 2009 Mar; 50(3):475-9. PubMed ID: 19054403
[TBL] [Abstract][Full Text] [Related]
23. The LAM-SAFE Study: lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults.
Steinhoff BJ; Ueberall MA; Siemes H; Kurlemann G; Schmitz B; Bergmann L;
Seizure; 2005 Dec; 14(8):597-605. PubMed ID: 16278088
[TBL] [Abstract][Full Text] [Related]
24. Long-term effectiveness of ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy.
Hwang H; Kim H; Kim SH; Kim SH; Lim BC; Chae JH; Choi JE; Kim KJ; Hwang YS
Brain Dev; 2012 May; 34(5):344-8. PubMed ID: 21893390
[TBL] [Abstract][Full Text] [Related]
25. Time course of reversal of valproate-mediated inhibition of lamotrigine.
Leary E; Sheth RD; Gidal BE
Seizure; 2018 Apr; 57():76-79. PubMed ID: 29574285
[TBL] [Abstract][Full Text] [Related]
26. Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study).
Tompson DJ; Ali I; Oliver-Willwong R; Job S; Zhu L; Lemme F; Hammer AE; Vuong A; Messenheimer JA
Epilepsia; 2008 Mar; 49(3):410-7. PubMed ID: 17825077
[TBL] [Abstract][Full Text] [Related]
27. An active-control trial of lamotrigine monotherapy for partial seizures.
Gilliam F; Vazquez B; Sackellares JC; Chang GY; Messenheimer J; Nyberg J; Risner ME; Rudd GD
Neurology; 1998 Oct; 51(4):1018-25. PubMed ID: 9781523
[TBL] [Abstract][Full Text] [Related]
28. [Open study evaluating lamotrigine efficacy and safety in add-on treatment and consecutive monotherapy in adult patients with epilepsy resistant carbamazepine and valproate].
Jóźwiak S; Niedzielska K; Mańko E; Terczyński A
Neurol Neurochir Pol; 2000; 34(4):673-89. PubMed ID: 11105300
[TBL] [Abstract][Full Text] [Related]
29. Does lamotrigine influence valproate concentrations?
Mataringa MI; May TW; Rambeck B
Ther Drug Monit; 2002 Oct; 24(5):631-6. PubMed ID: 12352935
[TBL] [Abstract][Full Text] [Related]
30. Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy.
Kim JY; Lee HW
Epilepsia; 2007 Jul; 48(7):1366-70. PubMed ID: 17565596
[TBL] [Abstract][Full Text] [Related]
31. Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy.
Kaminow L; Schimschock JR; Hammer AE; Vuong A
Epilepsy Behav; 2003 Dec; 4(6):659-66. PubMed ID: 14698699
[TBL] [Abstract][Full Text] [Related]
32. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly.
Saetre E; Perucca E; Isojärvi J; Gjerstad L;
Epilepsia; 2007 Jul; 48(7):1292-302. PubMed ID: 17561956
[TBL] [Abstract][Full Text] [Related]
33. Lamotrigine XR conversion to monotherapy: first study using a historical control group.
French JA; Temkin NR; Shneker BF; Hammer AE; Caldwell PT; Messenheimer JA
Neurotherapeutics; 2012 Jan; 9(1):176-84. PubMed ID: 22139591
[TBL] [Abstract][Full Text] [Related]
34. Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy.
Gidal BE; Anderson GD; Rutecki PR; Shaw R; Lanning A
Epilepsy Res; 2000 Nov; 42(1):23-31. PubMed ID: 10996503
[TBL] [Abstract][Full Text] [Related]
35. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study.
Tomson T; Battino D; Bonizzoni E; Craig J; Lindhout D; Perucca E; Sabers A; Thomas SV; Vajda F;
Neurology; 2015 Sep; 85(10):866-72. PubMed ID: 26085607
[TBL] [Abstract][Full Text] [Related]
36. Blood homocysteine, folate and vitamin B-12 concentrations in patients with epilepsy receiving lamotrigine or sodium valproate for initial monotherapy.
Gidal BE; Tamura T; Hammer A; Vuong A
Epilepsy Res; 2005 May; 64(3):161-6. PubMed ID: 15936175
[TBL] [Abstract][Full Text] [Related]
37. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction.
Pisani F; Oteri G; Russo MF; Di Perri R; Perucca E; Richens A
Epilepsia; 1999 Aug; 40(8):1141-6. PubMed ID: 10448829
[TBL] [Abstract][Full Text] [Related]
38. The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy--an open-label, prospective, randomised controlled multicenter study.
Rosenow F; Schade-Brittinger C; Burchardi N; Bauer S; Klein KM; Weber Y; Lerche H; Evers S; Kovac S; Hallmeyer-Elgner S; Winkler G; Springub J; Niedhammer M; Roth E; Eisensehr I; Berrouschot J; Arnold S; Schröder M; Beige A; Oertel WH; Strzelczyk A; Haag A; Reif PS; Hamer HM;
J Neurol Neurosurg Psychiatry; 2012 Nov; 83(11):1093-8. PubMed ID: 22595362
[TBL] [Abstract][Full Text] [Related]
39. Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication.
May TW; Rambeck B; Jürgens U
Ther Drug Monit; 1996 Oct; 18(5):523-31. PubMed ID: 8885114
[TBL] [Abstract][Full Text] [Related]
40. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy.
Brodie MJ; Wilson EA; Wesche DL; Alvey CW; Randinitis EJ; Posvar EL; Hounslow NJ; Bron NJ; Gibson GL; Bockbrader HN
Epilepsia; 2005 Sep; 46(9):1407-13. PubMed ID: 16146435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
